GRAIL INC (NASDAQ:GRAL) Reports Mixed Q2 2025 Earnings: Revenue Misses, Loss Narrows

GRAIL INC (NASDAQ:GRAL [https://www.chartmill.com/stock/quote/GRAL/profile]) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. The company, which focuses on early cancer detection through its Galleri test, posted revenue of $35.5 million, falling short of the consensus estimate of $38.3 million. Meanwhile, its earnings per share (EPS) came in at -$3.18, slightly better than the anticipated -$3.64.

KEY FINANCIAL HIGHLIGHTS VS. ESTIMATES

* REVENUE MISS: Reported sales of $35.5 million fell 7.2% below expectations, signaling slower-than-expected adoption or reimbursement challenges.
* NARROWER LOSS: The EPS loss of -$3.18 was less severe than projected, suggesting cost controls or operational efficiencies may be improving.
* GALLERI TEST GROWTH: U.S. revenue from Galleri grew 21% year-over-year to $34.2 million, while tests sold increased 29% to over 45,000.

MARKET REACTION

Following the earnings release, GRAL shares declined 2.6% in after-hours trading. This suggests investor disappointment with the revenue miss, despite the narrower-than-expected loss. Over the past month, the stock has dropped 12.8%, reflecting broader market skepticism or concerns about the company’s path to profitability.

UPCOMING CATALYSTS

GRAIL highlighted that detailed results from its PATHFINDER 2 study—enrolling 25,000 participants—will be submitted for presentation at the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS IN OCTOBER 2025. This could serve as a near-term catalyst if the data reinforces the clinical utility of Galleri.

ANALYST EXPECTATIONS FOR FUTURE QUARTERS

* Q3 2025: Analysts forecast revenue of $35.3 million and an EPS loss of -$3.58.
* FULL-YEAR 2025: Estimated sales stand at $148.8 million, with an EPS loss of -$14.23.

While GRAIL continues to demonstrate growth in test adoption, the revenue shortfall raises questions about its ability to meet long-term sales targets. Investors will likely focus on upcoming clinical data and execution in reimbursement strategies.

For more detailed earnings estimates and historical performance, see GRAIL’s earnings estimates [https://www.chartmill.com/stock/quote/GRAL/earnings-estimates].

_Disclaimer: This article is for informational purposes only and does not constitute investment advice._